|
Gene: MARC1 |
Gene summary for MARC1 |
Gene summary. |
Gene information | Species | Human | Gene symbol | MARC1 | Gene ID | 64757 |
Gene name | mitochondrial amidoxime reducing component 1 | |
Gene Alias | MARC1 | |
Cytomap | 1q41 | |
Gene Type | protein-coding | GO ID | GO:0006082 | UniProtAcc | Q5VT66 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
64757 | MARC1 | LZE2T | Human | Esophagus | ESCC | 9.54e-06 | 5.03e-01 | 0.082 |
64757 | MARC1 | LZE22T | Human | Esophagus | ESCC | 1.57e-03 | 2.11e-01 | 0.068 |
64757 | MARC1 | P1T-E | Human | Esophagus | ESCC | 2.97e-02 | 1.54e-01 | 0.0875 |
64757 | MARC1 | P2T-E | Human | Esophagus | ESCC | 7.31e-14 | 2.49e-01 | 0.1177 |
64757 | MARC1 | P4T-E | Human | Esophagus | ESCC | 1.22e-08 | 2.55e-01 | 0.1323 |
64757 | MARC1 | P5T-E | Human | Esophagus | ESCC | 2.05e-07 | 2.10e-01 | 0.1327 |
64757 | MARC1 | P8T-E | Human | Esophagus | ESCC | 1.66e-02 | 8.32e-02 | 0.0889 |
64757 | MARC1 | P9T-E | Human | Esophagus | ESCC | 1.45e-04 | 1.38e-01 | 0.1131 |
64757 | MARC1 | P15T-E | Human | Esophagus | ESCC | 3.26e-02 | 8.77e-02 | 0.1149 |
64757 | MARC1 | P16T-E | Human | Esophagus | ESCC | 1.23e-20 | 4.12e-01 | 0.1153 |
64757 | MARC1 | P19T-E | Human | Esophagus | ESCC | 6.53e-04 | 2.71e-01 | 0.1662 |
64757 | MARC1 | P20T-E | Human | Esophagus | ESCC | 5.73e-03 | 9.65e-02 | 0.1124 |
64757 | MARC1 | P22T-E | Human | Esophagus | ESCC | 1.88e-04 | 1.25e-01 | 0.1236 |
64757 | MARC1 | P23T-E | Human | Esophagus | ESCC | 2.24e-15 | 3.70e-01 | 0.108 |
64757 | MARC1 | P24T-E | Human | Esophagus | ESCC | 9.53e-09 | 1.77e-01 | 0.1287 |
64757 | MARC1 | P28T-E | Human | Esophagus | ESCC | 3.58e-28 | 5.33e-01 | 0.1149 |
64757 | MARC1 | P30T-E | Human | Esophagus | ESCC | 2.19e-27 | 1.05e+00 | 0.137 |
64757 | MARC1 | P31T-E | Human | Esophagus | ESCC | 2.05e-07 | 1.50e-01 | 0.1251 |
64757 | MARC1 | P36T-E | Human | Esophagus | ESCC | 2.11e-03 | 1.67e-01 | 0.1187 |
64757 | MARC1 | P37T-E | Human | Esophagus | ESCC | 2.31e-05 | 1.33e-01 | 0.1371 |
Page: 1 2 3 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MARC1 | SNV | Missense_Mutation | novel | c.835N>A | p.Asp279Asn | p.D279N | Q5VT66 | protein_coding | tolerated(0.14) | possibly_damaging(0.812) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
MARC1 | SNV | Missense_Mutation | rs140778482 | c.496N>A | p.Ala166Thr | p.A166T | Q5VT66 | protein_coding | deleterious(0.01) | possibly_damaging(0.753) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MARC1 | SNV | Missense_Mutation | c.458G>A | p.Gly153Asp | p.G153D | Q5VT66 | protein_coding | deleterious(0.02) | benign(0.069) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
MARC1 | SNV | Missense_Mutation | rs141446287 | c.332G>A | p.Arg111His | p.R111H | Q5VT66 | protein_coding | deleterious(0.04) | probably_damaging(0.995) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
MARC1 | SNV | Missense_Mutation | rs766619677 | c.847G>A | p.Gly283Ser | p.G283S | Q5VT66 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MARC1 | SNV | Missense_Mutation | novel | c.980A>T | p.Lys327Ile | p.K327I | Q5VT66 | protein_coding | deleterious(0.01) | possibly_damaging(0.609) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
MARC1 | SNV | Missense_Mutation | novel | c.287T>C | p.Val96Ala | p.V96A | Q5VT66 | protein_coding | deleterious(0) | probably_damaging(0.976) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MARC1 | SNV | Missense_Mutation | rs72470601 | c.739N>A | p.Asp247Asn | p.D247N | Q5VT66 | protein_coding | tolerated(0.18) | benign(0.003) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MARC1 | SNV | Missense_Mutation | rs371910688 | c.718A>G | p.Asn240Asp | p.N240D | Q5VT66 | protein_coding | deleterious(0) | possibly_damaging(0.889) | TCGA-EY-A1G8-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MARC1 | SNV | Missense_Mutation | novel | c.328N>A | p.Pro110Thr | p.P110T | Q5VT66 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-EY-A1GM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | PD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |